ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

32704 results sorted by trial registration date.
  • Dementia Care Mapping in residential aged care

    Dementia Care Mapping (DCM) employs detailed observations of persons with dementia to identify factors which promote their well-being and ill-being. This provides the basis for health service delivery which is person-centred and focused on the resident's well-being. Consequently, the persons' behavioural disturbance will reduce. This is a randominsed control study conducted over 2 years with 360 persons with dementia , with 200 care staff in 15 matched residential dementia care units in a prepost test, followup design.

  • Doxorubicin Transdrug® in Advanced Hepatocellular Carcinoma.

    The objective of the trial is to compare the efficacy (based on time to progression of tumour) and tolerance of Hepatic Intra-Arterial injection of Doxorubicin Transdrug® every 4 weeks, up to 3 courses with control standard treatment according to each centre’s usual practice (including TACE). This is an open label, multicentre, randomized in two parallel groups, Phase 2-3 study. The trial is designed to be performed in two successive parts, Phase 2 and Phase 3. At the end of the Phase 2, the efficacy of Doxorubicin Transdrug® will be evaluated based on the rate of patient free of local progression 3 months after randomisation. If more than 66% of patients treated with Doxorubicin Transdrug® are free of local progression, the study will be pursued and patients included in the Phase 2 study will automatically be followed and analyzed in the Phase 3 study. A total of 200 patients will be accrued of whom 50 patients will be accrued for the Phase 2. Patients satisfying inclusion and exclusion criteria will be centrally randomised to one of two treatments groups. Group A: Patients will receive a course of hepatic intra-arterial Doxorubicin Transdrug® on Day1. The treatment will be repeated every 4 weeks or until D90 (i.e. 3 months after randomization) for a total of 3 courses in the absence of disease progression or unacceptable toxicity. Group B: Patients will receive treatment according to each centre’s usual practice (including TACE), treatment will be repeated until D90 (i.e. 3 months after randomization) in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for one year.

  • Evaluation of a group program for anxious adolescents who have been bullied at school

    The primary purpose of the study was to evaluate the effectiveness of a program that aimed to build coping skills for adolescents who were being bullied at school. We predicted that adolecents who completed the program would reported less bullying, reduced impact of being bullied, and lower symptoms of anxiety and depression than adolescents who had been allocated to a wait-list control condition.

  • An exploration of the antioxidant, immunomodulatory, and anti-inflammatory activities of Ambrotose in healthy individuals.

    The study is a double blind, placebo controlled, randomised trial to be conducted over 6 weeks in parallel groups of otherwise healthy individuals. The study will compare baseline in vivo and ex vivo changes of antioxidant levels and various immune cell functions with end of study outcomes.

  • Comparison of partial coherence tonometry and ultrasound biometry

    The objective of this trial was specifically aimed at answering the research question: For the general cataract population, does the use of partial coherence interferometry improve postoperative outcomes compared with current generation applanation ultrasound biometry, as measured by postoperative refractive error, by increasing the accuracy of calculation of the intraocular lens power.

  • The Despatch Trial: DElivering Stroke Prevention for patients with ATrial fibrillation: a Cluster randomised controlled trial in a primary Health care setting.

    Non-valvular atrial fibrillation (NVAF) is a common heart condition associated with a major risk of fatal and disabling stroke. Inexpensive anticoagulant medication has been proven to reduce all-cases of death and stroke in people with NVAF. Anticoagulant treatment for NVAF is substantially underused resulting in avoidable patient deaths and disabling stroke. This study seeks to optimise the management of NVAF in general practice. We are developing an educational program for general practitioners which we hypothesis will increase the number of people with NVAF over the age of 65 who are prescribed anticoagulant medication.

  • Study of Environment on Aboriginal Resilience and Child Health

    The question is whether a health broker being involved in the care of a child with otitis media can improve the care of that child. This will be measured by seeing whether children with access to a health broker follow the doctor's care plan more closely than children without a health broker

  • Bare Metal BifuRcAtion SteNt Clinical Trial in Humans (IP088) With Coronary Stenosis At or Near a Vessel Bifurcation - Safety at 30-Days

    A prospective multi-center, non-randomized, single arm trial enrolling up to 60 patients with symptomatic ischemic heart disease attributable to a bifurcation lesion that is amenable to percutaneous treatment with stenting. A bifurcation lesion must have =/> 50% stenosis in the main branch. Trial patients may have multiple vessel disease but only a single bifurcation lesion per patient mmay be treated during the trial procedure, with no other lesions of any type treated at this time-point. Clinical follow-up assessment will be performed at 30-days post procedure. Patient contact for follow-up assesment will be performed at 6 months, 9 months and 12 months post-procedure

  • The effectiveness of spinal manipulative therapy (SMT) versus Graston therapy (GT) in the treatment of non-specific thoracic pain: A randomised controlled trial

    At present only one randomized controlled trial has been performed assessing the effectiveness of spinal manipulative therapy on thoracic spinal pain (Schiller 1999). Several limitations were observed resulting in the Schiller concluding that further studies are required. Graston therapy is a massage system revolving around several hand-held stainless steel instruments (Graston Technique 2006). The founders claim that the instruments have the ability to detect fascial adhesions and restrictions, aiding in achieving improved outcomes for conditions such as thoracic pain (Graston Technique 2006). No high quality trials have been performed to test the efficacy and effectiveness of this method. Given the popularity of spinal manipulation and massage for back pain and the lack of data there is a need for further high quality studies The objective of this investigation is to determine the effectiveness of SMT and GT compared to a pseudo-sham in the treatment of non specific thoracic spine pain. Specifically, the null hypotheses are: 1. Perception of pain as measured by a 100mm visual analogue scale (VAS) will not differ between groups after 3 weeks of either SMT, GT or detuned short wave diathermy and detuned ultrasound 2. Function as measured by the Oswestry Back Pain Disability Index will not differ between groups under these study conditions

  • Ultrasound Guided Three-in-One Nerve Block for the Relief of Acute Pain from Fractured Neck of Femur. A Double-Blind, Randomised, Controlled Trial.

    This study is of pain relief for people with a broken hip (fractured neck of femur) in the period between arriving at the Emergency Department and having an operation. Standard treatment of pain is by injections of morphine as required. This study will look at injecting long acting local anaesthetic to the nerves which supply the hip. An ultrasound machine will be used to accurately place the injection. It is hoped that this will give better pain relief than morphine alone with less side effects of nausea and drowsiness. The local anaesthetic is expected to last about 18 hours. This will cover the period from the Emergency Department to Operating Theatre for many patients. Doctors, Nurses and Patients will not know whether local anaesthetic or a saline placebo has been injected. All patients will be given as much morphine as is necessary to control their pain.

Tags:
  • Finding clinical trials